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Abstract
Several new methods of renal replacement therapy (RRT) are now available for treating patients in the ICU setting.
However, utilization of RRT in the ICU is subject to considerable variation and the need for RRT is associated with
worse outcomes. Several factors influence the application of dialysis and reflect the interplay of patient and process
of care elements that are dynamic in nature. Despite multiple studies evaluating RRT and its application, there are
gaps in our knowledge that must be overcome to improve outcomes. This article discusses some of the important
issues that require attention in delivering RRT in critically ill patients and provides a framework for the optimal use
of RRT in the ICU.
Introduction
Over the last three decades, various modalities of renal
replacement therapy (RRT) have been utilized for mana-
ging patients in the ICU setting. Advances in technology
have resulted in smarter machines that can be custo-
mized to remove solute and manage fluids to meet a
wide spectrum of clinical situations. Intermittent hemo-
dialysis (IHD) and peritoneal dialysis (PD), the mainstays
of dialysis for end-stage renal disease (ESRD), have been
complemented with the development of several modal-
ities of continuous renal replacement therapy (CRRT)
[1]. Modifications in operational characteristics and the
time available for each session has contributed to newer
methods for extended dialysis (e.g., slow low-efficiency
daily dialysis (SLEDD)) and have added to the available
modalities for RRT [2]. Despite this progress, however,
there has been limited success in improving outcomes
in patients who are treated with RRT in the ICU. The
considerable variation that exists in the application of
RRT in the ICU reflects the lack of standardization in
this field. The interplay of underlying patient character-
istics, process of care, and external events probably con-
tributes to that variation and may influence outcomes.
This article reviews important issues to be considered
for the optimal use of RRT in the critically ill.
Challenges for RRT in the ICU
Determining goals for therapy
Defining the goals of therapy is a key consideration in the
use of RRT in the ICU. Critically ill patients span the
spectrum of severity at initial evaluation, and changes in
severity of illness occur commonly and predict outcomes.
Process of care factors (e.g., fluid resuscitation, ventilator
requirements, and nutritional support) further influence
patient needs. Consequently, therapeutic modalities need
to support organ function through the continuum of cri-
tical illness. Unfortunately, there is no consensus on the
goals for therapy with RRT in the ICU. In most instances,
clinicians consider RRT only as a means to address ure-
mic symptoms or biochemical evidence of solute and
fluid imbalance. Life-threatening events such as severe
hyperkalemia with electrocardiogram (ECG) changes,
marked acid-base abnormalities, and diuretic unrespon-
sive fluid overload or central nervous system (CNS) man-
ifestations attributed to uremia are common events
managed with RRT. As a result, RRT is only offered
when there is clear evidence of functional deterioration
to a point at which the kidney is unlikely to recover
quickly enough to avoid the deleterious consequences of
altered renal function. This approach is largely based on
experience with ESRD patients where dialysis is only
initiated when the glomerular filtration rate (GFR) has
declined to <5-10 ml/minute and the patient is sympto-
matic. This approach is problematic in ICU patients with
acute kidney injury (AKI), because the strategy in treating
AKI is to minimize and avoid uremic complications,
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whereas in ESRD the aim is to keep the patient off dialy-
sis as long as possible. Thus, it is not necessary to wait
for progressive uremia as the only goal for RRT. For
instance, excessive volume resuscitation, a common strat-
egy used for multiorgan failure (MOF), may result in
fluid accumulation and overload even when kidney func-
tion is not completely compromised [3]. In these
instances, fluid removal to achieve fluid balance could be
considered a therapeutic target for RRT. In fact, given
the versatility of RRT techniques to maintain metabolic
and fluid balance, RRT should be considered a means to
maintain homeostasis. CRRT is particularly well suited to
provide renal support in the ICU patient. The freedom to
provide continuous fluid management permits the appli-
cation of unlimited nutrition, adjustments in hemody-
namic parameters, and achievement of steady-state
solute control–benefits which are difficult to attain with
intermittent therapies.
When is the ideal time to start RRT?
Several issues must be considered, including the timing
of the intervention, the amount and frequency of dialysis,
and the duration of therapy. In practice, these issues are
based on individual physician preferences and experience;
no set criteria are followed [4]. A major factor is the
heterogeneity in presentation of AKI that can occur de
novo or can be superimposed on chronic kidney disease
(CKD). A lack of specific symptoms other than oliguria
further hampers recognition, particularly in ICU patients
for whom symptoms that could be attributable to kidney
injury may not be as evident and other organs compete
for attention. Some observational studies and a few ran-
domized trials have evaluated the timing of dialysis initia-
tion and outcomes [5]. In most of these studies, arbitrary
cutoff values of blood urea nitrogen (BUN) and serum
creatinine were used to define the timing of initiation as
early or late. In critically ill patients with AKI, these bio-
markers are not reliable as measures to guide initiation of
RRT. BUN levels are influenced by tubular reabsorption
of urea, protein intake, catabolism, volume status, upper
gastrointestinal bleeding, and use of corticosteroids.
Serum creatinine has a nonlinear correlation to kidney
function. In AKI, unstable creatinine production, reduced
muscle mass, aging, use of drugs interfering with tubular
secretion, and variations within the creatinine assay make
serum creatinine a nonreliable marker of the GFR. More
recent studies have looked at AKI staging criteria and use
of novel kidney damage biomarkers to initiate RRT but
have had limited success.
Another area of concern that conditions the timing of
RRT is the risk for adverse consequences associated
with the procedure, including hypotension, bleeding,
dialysis catheter-related complications, etc. An “early”
RRT initiation would potentially expose a patient who
could spontaneously recover kidney function to unne-
cessary risks [4]. Moreover, RRT could impede kidney
recovery and increase the risk of progression to CKD.
Whether these risks could outweigh the potential bene-
fits of earlier initiation of RRT is debatable [6-8]. The
current lack of consensus forces individual physicians to
weigh the fear of adverse consequences against the
potential therapeutic benefits [9-11].
Given the uncertainty for identifying an ideal time for
initiating RRT, a conceptual framework has been devel-
oped that can be applied easily. In our institution, we
recommend considering that the kidney has a finite capa-
city to support other organ functions. Consequently, the
need to initiate dialysis should be prompted by the ability
of the kidney to meet the demands being placed on it. We
propose that RRT could be initiated when there is a mis-
match of demand and capacity [7]. As shown in Table 1
several conditions would prompt a mismatch. In most
instances, the criteria for initiating RRT would be indivi-
dualized and based on the existing dynamic conditions
rather than on any set of absolute conditions that would
need to be met. Although additional research is needed,
we would recommend that clinicians consider the decision
process of initiating RRT a dynamic one and assess
patients for the potential demand and the renal capacity
available to meet the demand.
What dose should be delivered?
Optimization of the delivered treatment dose has been
studied in several clinical trials of dialysis in AKI that
have yielded conflicting results [12-15]. These trials have
focused on small solute clearances as sole measures of
the RRT dose [16]. While solute removal is a key feature
of all RRT techniques, operational characteristics differ
among delivery modalities (Table 1). Diffusion-based
techniques similar to IHD are based on the principle of
maintaining a solute gradient between the blood and the
dialysate. High blood (250-400 ml/minute) and dialysate
(500-800 ml/minute) flow rates maintain the gradient, and
the dialysate composition can be varied to achieve solute
and acid-base balance. Convective techniques include
ultrafiltration and hemofiltration and depend on solute
removal by solvent drag [1]. Small molecules are preferen-
tially removed by diffusive methods while larger molecules
are more efficiently removed by this convection process;
hence, middle molecular clearances are superior. Varia-
tions in the time for which RRT is applied (3-4 hours for
IHD, 6-12 hours for SLEDD, and 24 hours for CRRT) and
alterations in the operational characteristics to harness dif-
fusive and convective clearance distinguish the different
modalities. In CRRT the dialysate flow rates are signifi-
cantly slower than the blood flow rates (typically blood
flow rates are 100-200 ml/minute, whereas dialysate
flow rates are 1-2 l/hour (17-34 ml/minute)). This flow
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disparity results in complete saturation of the dialysate [1].
In studies involving CRRT, the dose has been prescribed
as a weight-based hourly effluent rate and the delivered
dose is considered the measured effluent volume. How-
ever, solute clearance may be compromised in delivering
the prescribed dose continuously for the full 24 hours due
to concentration polarization of the filter, filter clotting,
and other factors including access-related problems and
external ICU procedures (e.g., surgery, computed tomo-
graphy scanning) that can reduce total treatment time
[17-21]. Similarly in intermittent techniques, hemody-
namic instability, shortened dialysis times, and logistic
factors often impact adversely on the dose delivered. The
effluent rate-based prescribed dose should be incremented
by 20-25% to account for decreases in treatment time and
lack of filter efficacy in CRRT [24].
Fluid removal to achieve fluid balance is another com-
ponent of the dose that has not been considered in
most trials (Table 2) [22,23]. Fluid removal in RRT is
achieved through varying amounts of ultrafiltration that
can be tailored to individual need. In contrast to inter-
mittent techniques where fluid balance by necessity
depends upon the time available to remove fluid, in
CRRT a targeted intervention for fluid balance to achieve
any particular hemodynamic parameter is possible [7].
While ultrafiltration requires fluid removal only, hemofil-
tration necessitates partial or complete replacement of
the fluid removed. The composition of the replacement
fluid can be varied and the solution can be infused pre
filter or post filter. In CRRT, the dose of dialysis delivered
is not time dependent. A major distinction for these
methods is the ability to dissociate solute removal (e.g.,
sodium) from fluid balance. As an example, by varying
the composition of the replacement fluid or dialysate
solute, the balance can be altered and maintained at low,
high, or normal levels, while fluid balance can be kept
net even, negative, or positive. Fine-tuning of fluid bal-
ance on an ongoing basis makes these techniques the
most versatile option.
What modality should be used?
The primary indication for dialytic intervention can be a
major determinant of the therapy chosen because differ-
ent therapies vary in their efficacy for solute and fluid
Table 1. Renal replacement therapy support based on underlying demand and capacity framework
Demand Capacity Example Action
High Normal High catabolic state Reduce demand if possible
High nutritional loading Monitor for renal support
Poisoning
High Low Decreased GFR from AKI Renal support
Reduce demand if possible
Normal Low CKD Add renal support if necessary to maintain steady state
Noncatabolic
AKI
Low Low Malnutrition and wasting CKD Assess for nutritional state and add renal support if necessary
AKI acute kidney injury, CKD chronic kidney disease, GFR glomerular filtration rate
Table 2. Proposed parameters for delivered dose assessment
Parameter Measurement Tools
Solute
Very small waste products K+, Na+, phosphate Blood levels of K, Na, PO4
Phosphate clearance
H- pH, HCO3 AG, SIDeff, SIDapp, SIG, Delta gap, Delta ratio
Small waste products Urea Clearance (ml/minute)
EKR (ml/minute)
Standard Kt/V
Middle sized molecules Serum b2-microglobulin b2-Microglobulin clearance
Fluid Weight (kg) Weight changes
Inputs-outputs Fluid accumulation
Bioelectrical impedance Fluid overload
BNP Bioimpedance vector analysis
BNP profile
AG anion gap, BNP brain natriuretic peptide, EKR equivalent urea clearance, H- ions, HCO3 bicarbonate, K potassium, Na sodium, PO4 phosphate, SIDapp apparent
strong ion difference, SIDeff effective strong ion difference
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removal. In the ICU, indications for renal replacement
are diverse and require modification based on the clinical
situation. For instance, if the indication for dialysis is to
facilitate the removal of a drug, such as theophylline in a
patient with a drug overdose, IHD is a logical choice,
given its efficacy and rapidity of response. If the indica-
tion is fluid removal, as in the hemodynamically unstable
postcardiac surgery patient, CRRT is preferable. In most
patients, however, the indication for dialysis may not be
as clear cut, and both solute and fluid removal are
desired. In this case, the course of the desired response
will also influence this decision. Life-threatening hyper-
kalemia in an otherwise stable patient is probably better
treated with IHD, whereas in the catabolic patient with
AKI who is hemodynamically stable the selection would
need to be based on other criteria. The presence of MOF
can influence the choice of RRT in two ways. First, the
presence of MOF may limit the choice of therapies; for
example, patients with abdominal surgery may not be
suitable for PD because it increases the risk of wound
dehiscence and infection [4]. Patients who are hemody-
namically unstable may not tolerate IHD [19]. Second,
the requirement for anticoagulation depends on the pre-
sence of coagulation abnormalities. PD avoids anticoagu-
lation, and IHD can be performed with saline flushes;
however, CRRT is difficult without anticoagulation.
Recognition of the key features of each of the RRT mod-
alities allows them to be used effectively for the appropri-
ate management of complex patients.
How long should RRT be continued?
RRT for AKI is based on the premise that kidney function
will eventually return and that dialysis can be discontin-
ued. Although this outcome is desirable, it does not always
occur. This is particularly true for the patient with AKI
and MOF, where the ultimate prognosis depends on the
recovery of other organ systems. In this situation, dialytic
support may only prolong the time to death and must be
instituted only when the goals and endpoint of therapy
have been defined. A “trial” of dialysis therapy should be
negotiated with the patient’s family and other critical care
personnel [24]. This trial facilitates withdrawal of dialysis
if there is no likelihood of recovery. For instance, an older
patient with respiratory, cardiac, and liver failure second-
ary to sepsis who requires dialytic support for AKI should
have a finite period of dialysis (1-2 weeks) and be reas-
sessed for evidence of improvement in all organ systems.
If there is no likelihood of recovery, withdrawal of dialysis
must be considered.
Pitfalls for RRT in the ICU
Maintaining the circuit
A key consideration for all RRT techniques is maintain-
ing the integrity of the circuit to enable adequate solute
and fluid management [25,26]. A functioning vascular
access that can deliver the required amount of blood
flow through the duration of the procedure is a key fac-
tor. Patency of the extracorporeal circuit requires the
use of anticoagulation which adds to the risk of compli-
cations and requires monitoring [27]. Several methods
of anticoagulation are now in use and it is possible to
minimize the risks. Several protocols are now available
for regional citrate anticoagulation for CRRT that have
been shown to be more effective than heparin regimens
for maintenance of patency [1,28]. Monitoring for antic-
oagulant efficacy has some unique practical conse-
quences (particularly for CRRT) that often limit effective
use of these therapies.
Achieving fluid balance
Fluid removal is a desirable component of any RRT and
is a major goal of RRT in the ICU [22] Volume overload
may be an independent contributor to mortality in ICU
patients, and thus is important to address, even in the
absence of uremia [3]. Fluid removal in IHD is easily
achieved in most cases with adequate blood pressure and
cardiac performance. However, because the process has
to be completed during 3-4 hours every day, the rate of
fluid removal has to be high. As a consequence, large
shifts in fluid balance generally result and contribute to
hemodynamic instability [29]. Additionally, fluid
removal–and hence fluid balance–is limited to the period
of dialysis. If the patient is hemodynamically unstable
during this period it may be difficult to remove any fluid.
By contrast, CRRT has the advantage of providing renal
replacement continuously and hence fluid removal or
replacement can be precisely adjusted for each patient
[7]. Because the process is gradual, hemodynamic stabi-
lity is easily maintained, and these therapies allow
ongoing modulation of fluid balance and targeted fluid
management. The high efficacy of these therapies in con-
tinuous fluid removal lends them for use in situations
other than renal failure [22].
Adjusting drug doses
Drug removal by RRT depends on the molecular weight,
charge, and protein binding of the drug [30]. Drugs
such as vancomycin and aminoglycosides are easily
removed and doses need to be supplemented [14]. Pro-
tein-bound drugs (e.g., digoxin) are minimally removed.
However, it should be recognized that drug clearances
may vary if the circuit is compromised. This is particu-
larly important for CRRT techniques where anticipated
drug removal does not occur when the circuit is clotted
or the therapy is interrupted [20]. Therapeutic drug
monitoring and drug adjustments are necessary to pre-
vent underdosing and overdosing of drugs during RRT.
Several resources now exist for managing drug dosing
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for patients on RRT. The same principles also apply to
nutritional support where amino acid losses occur
across the filter. Fluid balance can, however, be more
easily maintained with RRT, providing an opportunity to
maintain adequate nutritional support.
Procedure-related complications
Complications associated with RRT can result on several
fronts. Access-related complications can result from cir-
cuit disruptions with subsequent blood loss. Connections
should be taped to prevent accidental disconnection.
Since CRRT requires anticoagulation for longer periods,
the risk for complications related to anticoagulation is
higher, although this has not been the case in our experi-
ence [1,12,13]. In intermittent therapies, large, rapid
alterations in fluid and solutes occur over a short period,
so hemodynamic instability–reflected by hypotension
and cardiac arrhythmias–is encountered in approxi-
mately 25-50% of dialysis patients [31]. Recent studies
have demonstrated regional wall motion abnormalities
and myocardial stunning in IHD patients that correlate
with the volume and rate of fluid removal [32]. A major
area of concern is that episodes of hypotension during
dialysis can impact negatively on renal and patient out-
comes. Most patients treated with CRRT maintain hemo-
dynamic stability and tolerate the procedure well [12,13].
Continuous therapies have the potential for volume
depletion, particularly if monitoring is inadequate and
calculations are inaccurate. Because large volumes of
fluid can be removed quickly, meticulous monitoring is
essential, requiring a nurse-patient ratio of at least 1:1, if
not more. A major concern is that the continuous nature
of these therapies provides a greater opportunity for
manipulations by inexperienced personnel. It has been
our experience that these can be limited by standardiza-
tion of protocols for use of these therapies and restricting
their use to trained personnel.
Requirement for mobility
A major consideration in the choice of therapy is the
requirement of patient mobility [33]. If patients are to
be moved for different investigations, for trips to the
operating room, or in the bed for different procedures,
continuous therapies become more difficult to imple-
ment. Several strategies can be utilized to optimize
mobility. Temporary disconnections from CRRT with
recirculation through the filter with saline can be done
for 2-3 hours to permit patient mobilization. With use
of jugular vein access, patients can be moved from bed
to chair and can ambulate even when CRRT is running.
Structured physiotherapy exercises can be incorporated
in the RRT regimen to facilitate patient mobility and
return to health.
Summary
RRT offers a unique set of tools to manage critically ill
patients. Although traditional use of RRT has been rele-
gated to patients with severely compromised renal func-
tion, they can be applied effectively to provide organ
support. Available methods can be selected and adapted
to fit any virtually any given situation. Further research
is required to identify the patient populations most
likely to benefit and to define criteria for appropriate
timing of intervention with these therapies. Innovations
in technology with newer membranes and combination
therapies (e.g., sorbent-based dialysis) are emerging and
will enable these therapies to expand to other arenas. It
is apparent that to improve outcomes we need to imple-
ment our best approaches to optimizing the use of RRT
with standardized protocols.
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